Availability of information for dosing injectable medications in underweight or obese patients

Kimberly A. Jacques, Brian L Erstad

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose. Product information and pivotal studies on newly marketed injectable medications were reviewed to determine whether a weight descriptor was included and if information was provided for dosing patients with extremes of body weight. Methods. Products with new drug applications approved by the Food and Drug Administration between January 1, 2004, and January 30, 2009, were evaluated. Any information related to weight descriptors or dosing of patients with extremes of weight (body mass index of <18.5 or >40 kg/m2) relative to age and height was extracted from the product labeling or pivotal studies. Pharmaceutical companies were contacted if pivotal studies had not been published. The information was evaluated with a dosing usefulness score of 0-3; a score of 2 or greater was considered minimally adequate for dosing patients with extremes of weight. Results. Of the 84 medications evaluated, some reference to weight descriptors was found for 23 (27%). None had a calculated usefulness score of 2 or above based on information from product information or pivotal trials. Conclusion. Information from product labeling and pivotal studies involving newly marketed injectable medications is inadequate for dosing patients with extremes of weight.

Original languageEnglish (US)
Pages (from-to)1948-1950
Number of pages3
JournalAmerican Journal of Health-System Pharmacy
Volume67
Issue number22
DOIs
StatePublished - Nov 15 2010

Fingerprint

Thinness
Weights and Measures
Injections
Product Labeling
United States Food and Drug Administration
Pharmaceutical Preparations
Body Mass Index
Body Weight

Keywords

  • Dosage
  • Drug information
  • Injections
  • Labeling
  • Methodology
  • Obesity
  • Thinness
  • Weight

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Medicine(all)

Cite this

Availability of information for dosing injectable medications in underweight or obese patients. / Jacques, Kimberly A.; Erstad, Brian L.

In: American Journal of Health-System Pharmacy, Vol. 67, No. 22, 15.11.2010, p. 1948-1950.

Research output: Contribution to journalArticle

@article{e77fead61ac941f7921869817039b000,
title = "Availability of information for dosing injectable medications in underweight or obese patients",
abstract = "Purpose. Product information and pivotal studies on newly marketed injectable medications were reviewed to determine whether a weight descriptor was included and if information was provided for dosing patients with extremes of body weight. Methods. Products with new drug applications approved by the Food and Drug Administration between January 1, 2004, and January 30, 2009, were evaluated. Any information related to weight descriptors or dosing of patients with extremes of weight (body mass index of <18.5 or >40 kg/m2) relative to age and height was extracted from the product labeling or pivotal studies. Pharmaceutical companies were contacted if pivotal studies had not been published. The information was evaluated with a dosing usefulness score of 0-3; a score of 2 or greater was considered minimally adequate for dosing patients with extremes of weight. Results. Of the 84 medications evaluated, some reference to weight descriptors was found for 23 (27{\%}). None had a calculated usefulness score of 2 or above based on information from product information or pivotal trials. Conclusion. Information from product labeling and pivotal studies involving newly marketed injectable medications is inadequate for dosing patients with extremes of weight.",
keywords = "Dosage, Drug information, Injections, Labeling, Methodology, Obesity, Thinness, Weight",
author = "Jacques, {Kimberly A.} and Erstad, {Brian L}",
year = "2010",
month = "11",
day = "15",
doi = "10.2146/ajhp100226",
language = "English (US)",
volume = "67",
pages = "1948--1950",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "22",

}

TY - JOUR

T1 - Availability of information for dosing injectable medications in underweight or obese patients

AU - Jacques, Kimberly A.

AU - Erstad, Brian L

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Purpose. Product information and pivotal studies on newly marketed injectable medications were reviewed to determine whether a weight descriptor was included and if information was provided for dosing patients with extremes of body weight. Methods. Products with new drug applications approved by the Food and Drug Administration between January 1, 2004, and January 30, 2009, were evaluated. Any information related to weight descriptors or dosing of patients with extremes of weight (body mass index of <18.5 or >40 kg/m2) relative to age and height was extracted from the product labeling or pivotal studies. Pharmaceutical companies were contacted if pivotal studies had not been published. The information was evaluated with a dosing usefulness score of 0-3; a score of 2 or greater was considered minimally adequate for dosing patients with extremes of weight. Results. Of the 84 medications evaluated, some reference to weight descriptors was found for 23 (27%). None had a calculated usefulness score of 2 or above based on information from product information or pivotal trials. Conclusion. Information from product labeling and pivotal studies involving newly marketed injectable medications is inadequate for dosing patients with extremes of weight.

AB - Purpose. Product information and pivotal studies on newly marketed injectable medications were reviewed to determine whether a weight descriptor was included and if information was provided for dosing patients with extremes of body weight. Methods. Products with new drug applications approved by the Food and Drug Administration between January 1, 2004, and January 30, 2009, were evaluated. Any information related to weight descriptors or dosing of patients with extremes of weight (body mass index of <18.5 or >40 kg/m2) relative to age and height was extracted from the product labeling or pivotal studies. Pharmaceutical companies were contacted if pivotal studies had not been published. The information was evaluated with a dosing usefulness score of 0-3; a score of 2 or greater was considered minimally adequate for dosing patients with extremes of weight. Results. Of the 84 medications evaluated, some reference to weight descriptors was found for 23 (27%). None had a calculated usefulness score of 2 or above based on information from product information or pivotal trials. Conclusion. Information from product labeling and pivotal studies involving newly marketed injectable medications is inadequate for dosing patients with extremes of weight.

KW - Dosage

KW - Drug information

KW - Injections

KW - Labeling

KW - Methodology

KW - Obesity

KW - Thinness

KW - Weight

UR - http://www.scopus.com/inward/record.url?scp=79952197484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952197484&partnerID=8YFLogxK

U2 - 10.2146/ajhp100226

DO - 10.2146/ajhp100226

M3 - Article

VL - 67

SP - 1948

EP - 1950

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 22

ER -